Estrogen absorption and metabolism in postmenopausal women with end- stage renal disease

Journal of Clinical Endocrinology and Metabolism

Volumn 81, Issue 12, 1996, Pages 4414-4417

  Ginsburg, Elizabeth S ^a   Owen Jr , William F ^a   Greenberg, Louise M ^a   Shea, Brian F ^a   Lazarus, J Michael ^a   Walsh, Brian W ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; ARTICLE; BLOOD SAMPLING; CAUSE OF DEATH; CLINICAL ARTICLE; DRUG ABSORPTION; ESTROGEN DEFICIENCY; ESTROGEN METABOLISM; FEMALE; HEMODIALYSIS; HUMAN; KIDNEY FAILURE; KIDNEY FUNCTION; LIPOPROTEIN METABOLISM; POSTMENOPAUSE; PRIORITY JOURNAL; SUBSTITUTION THERAPY;

ABSORPTION; AGED; ESTRADIOL; ESTROGEN REPLACEMENT THERAPY; FEMALE; HUMANS; KIDNEY FAILURE, CHRONIC; MIDDLE AGED; POSTMENOPAUSE; SERUM ALBUMIN; SEX HORMONE-BINDING GLOBULIN;

EID: 0029848686     PISSN: 0021972X     EISSN: None     Source Type: Journal    
DOI: 10.1210/jc.81.12.4414     Document Type: Article

References (14)

1. U.S. Renal Data System, USRDS. 1995 Annual data report. Bethesda: NIH, NIDDK.
2. Ma KW, Greene EL, Raij L. 1992 Cardiovascular risk factors in chronic renal failure and hemodialysis populations. Am J Kidney Dis. 19:505-513.
3. Joven J, Vilella E, Ahmad S, Cheung MC, Brunzell JD. 1993 Lipoprotein heterogeneity in end-stage renal disease. Kidney Int. 43:410-418.
4. Heimann P, Josephson MA, Fellner SK, Thistlewaite Jr JR, Stuart FP, Dasgupta A. 1991 Elevated lipoprotein(a) levels in renal transplantation and hemodialysis patients. Am J Nephrol. 11:470-474.
5. Cressman MD, Heyka RJ, Paganini FP, O'Neil J, Skibinski CI, Hoff HP. 1992 Lipoprotein(a) is an independent risk factor for cardiovascular disease in hemodialysis patients. Circulation. 86:475-482.
6. Nabulski AA, Folsom AR, White A, et al. 1993 Association of hormone-replacement therapy with various cardiovascular risk factors in postmenopausal women. N Engl J Med. 328:1069-1075.
7. Stampfer MJ, Colditz GA, Willett WC, et al. 1991 Postmenopausal estrogen therapy and cardiovascular disease. N Engl J Med. 325: 756-762.
8. Gorsky RD, Koplan JP, Peterson HB, Thacker SB. 1994 Relative risks and benefits of long-term estrogen replacement therapy: a decision analysis. Obstet Gynecol. 83:161-166.
9. Walsh BW, Schiff I, Rosner B, Greenberg L, Ravnikar V, Sachs FM. 1991 Effects of postmenopausal estrogen replacement on the concentration and metabolism of plasma lipoproteins. N Engl J Med. 325:1196-1204.
10. Sodergard R, Backstrom T, Shanbhag V, Carstensen H. 1982 Calculation of free and bound fractions of testosterone and estradiol-17β to human plasma proteins at body temperature. J Steroid Biochem. 16:801-810.
11. 14-estradiol in women. J Clin Invest. 36:1266-1278.
12. van Kammen E, Thijssen JHH, Donker GH, Schwarz F. 1975 The excretion of metabolites of testosterone and of estradiol in male patients with chronic renal failure. Steroids. 26:508-515.
13. Marple JT, MacDougall M. 1993 Development of malignancy in the end-stage renal disease patient. Semin Nephrol. 13:306-314.
14. Ginsburg ES, Owen WF. 1993 Reproductive endocrinology and pregnancy in women on hemodialysis. Semin Dial. 6:105-116.